Work

Durvalumab not cost‐effective with current pricing strategies for stage III NSCLC

Year: 2024

Type: article

Source: Cancer

DOI: 10.1002/cncr.35529

Author: Mary Beth Nierengarten

Language: English

Topic: Health Systems, Economic Evaluations, Quality of Life

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4402191966

FWCI: 0.362

Cites: 2

Cited by: 1

Related to: 10